Ifex Related Published Studies
Well-designed clinical trials related to Ifex (Ifosfamide / Mesna)
Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy. [1998.09]
Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group. [1996.08]
Phase II evaluation of ifosfamide/mesna in metastatic prostate cancer. A Southwest Oncology Group study. [1996.08]
A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. [1996.06]
Well-designed clinical trials possibly related to Ifex (Ifosfamide / Mesna)
Gemcitabine for the treatment of non-small-cell lung cancer. [2001.03]
Oral verapamil with chemotherapy for advanced non-small cell lung cancer: a randomised study. [1993.05]
Other research related to Ifex (Ifosfamide / Mesna)
A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. [2007.05]
Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study. [2006.02]
Ifosfamide-induced encephalopathy. [2002.10]
Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. [2000.04]
Phase II study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for patients with relapsed or refractory non-Hodgkin's lymphoma after failure to cytarabine/cisplatin combination. [1999]
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and consolidation with ESHAP for refractory and relapsed non-Hodgkin's lymphoma. [1998.12]
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. [1998.08]
A prospective phase II trial to evaluate the efficacy and toxicity of hepatic arterial infusion of ifosfamide in patients with inoperable localized hepatocellular carcinoma. [1997.06]
Effect of ifosfamide on intracellular glutathione levels in peripheral blood lymphocytes and its correlation with therapeutic response in patients with advanced ovarian cancer. [1997]
Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia. [1996.03]
Ifosfamide-induced nonconvulsive status epilepticus. [1995.12]
Continuous infusion of vincristine, ifosfamide and epirubicin over 6 weeks in treatment-resistant advanced breast cancer. [1995.10]
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. [1995.03]
Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study. [1995.02]
A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. [1995.01]
Phase II study of ifosfamide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer. [1994.12]
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. [1994.09]
Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. [1994]
A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas. [1994]
Ifosfamide. Patient care management. [1993.10]
Ifosfamide, mesna, and nephrotoxicity in children. [1993.01]
Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study. [1993]
Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. [1993]
Current studies of ifosfamide for pediatric solid tumors and leukemia in the United States. [1992.12]
A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer. [1992.12]
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. [1992.11.15]
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: cancer and leukemia group B study 8753. [1992]
Uroepithelial and nephrotubular toxicity in patients receiving ifosfamide/mesna: measurement of urinary N-acetyl-beta-D-glucosaminidase and beta-2-microglobulin. [1992]
Ifosfamide pharmacokinetics. [1991.11]
Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. [1991.11]
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. [1991.09]
Ifosfamide in the treatment of high-grade recurrent non-Hodgkin's lymphomas. [1991.07]
Chemotherapy with high dose ifosfamide/mesna plus cisplatin for the treatment of ovarian cancer: a study of the Grupo de Estudio y Tratamiento Latino-Americano del Cancer. [1991.03]
Ifosfamide and mesna for the treatment of advanced squamous cell head and neck cancer. A GETLAC study. [1991]
Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control. [1990.10]
Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. [1990.06.01]
Gynecologic Oncology Group experience with ifosfamide. [1990.04]
Early phase II Gynecologic Oncology Group experience with ifosfamide/mesna in gynecologic malignancies. [1990]
Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study. [1990]
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study. [1989.11]
Ifosfamide encephalopathy: a reappraisal. [1989.09]
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies. [1989.02]
Clinical studies of ifosfamide/mesna at St Jude Children's Research Hospital, 1983-1988. [1989.02]
Ifosfamide in pediatric malignant solid tumors. [1989]
The multidrug resistant phenotype in clinical practice; evaluation of cross resistance to ifosfamide and mesna after VP16-213, doxorubicin and vincristine (VPAV) for small cell lung cancer. [1988.02]
Ifosfamide/mesna related encephalopathy: a case report with a possible role of phenobarbital in enhancing neurotoxicity. [1988]
A phase II study of ifosfamide/mesna with doxorubicin for adult soft tissue sarcoma. [1988]
Other possibly related research studies
Docetaxel for previously treated non-small-cell lung cancer. [2002.06]
The role of mitoxantrone in non-Hodgkin's lymphoma. [2002.04]
Recombinant human thrombopoietin in myelosuppressive chemotherapy. [2001.07]
Paclitaxel in the treatment of advanced urothelial cancer. [2000.01]
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer. [2005.11]
Preradiation chemotherapy of children and young adults with malignant brain tumors: results of the German pilot trial HIT'88/'89. [1998.07]
Integration of filgrastim into chemoradiation for limited small cell lung cancer: a Phase I study. [1998.01.15]
Prophylactic granulocyte colony-stimulating factor allows escalation of chemotherapeutic dose intensity in advanced epithelial ovarian cancer. [1996.12]
Response of small cell carcinoma of pancreas to a small cell lung cancer regimen: a case report. [1996]
Design of new oxazaphosphorine anticancer drugs. [2007]
Cisplatin-based three drugs combination (NIP) as induction and adjuvant treatment in locally advanced non-small cell lung cancer: final results. [2008.02]
Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. [2004.11]
|
